ACE inhibitors or ARBs after ACS are recommended for which patients?

ACE inhibitors or ARBs after ACS are recommended for which patients?

• A. Only if heart failure or reduced EF
• B. For patients with HF/↓EF, diabetes, chronic kidney disease, and hypertension after ACS, and in all patients if not contraindicated
• C. Only for hypertensive patients
• D. Not recommended after ACS

Answer: (B)

Blocking the renin-angiotensin system after an acute coronary syndrome reduces mortality and helps prevent adverse cardiac remodeling. This benefit goes beyond just patients with heart failure or reduced EF; individuals with diabetes, chronic kidney disease, or hypertension also gain protection, because these drugs lower afterload and limit LV dilation, supporting better long-term function. Therefore, guidelines support starting an ACE inhibitor or ARB in most patients after ACS who can tolerate them, especially if there is LV dysfunction, HF, diabetes, CKD, or hypertension, and continuing in all eligible patients unless contraindicated. The other choices are too narrow: limiting use to those with heart failure or reduced EF misses other high-risk groups; limiting to hypertensive patients excludes those with diabetes or CKD who also benefit; and saying it’s not recommended after ACS is incorrect.

Blocking the renin-angiotensin system after an acute coronary syndrome reduces mortality and helps prevent adverse cardiac remodeling. This benefit goes beyond just patients with heart failure or reduced EF; individuals with diabetes, chronic kidney disease, or hypertension also gain protection, because these drugs lower afterload and limit LV dilation, supporting better long-term function. Therefore, guidelines support starting an ACE inhibitor or ARB in most patients after ACS who can tolerate them, especially if there is LV dysfunction, HF, diabetes, CKD, or hypertension, and continuing in all eligible patients unless contraindicated. The other choices are too narrow: limiting use to those with heart failure or reduced EF misses other high-risk groups; limiting to hypertensive patients excludes those with diabetes or CKD who also benefit; and saying it’s not recommended after ACS is incorrect.